Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Edesa Biotech, Inc. (EDSA) ownership reporting by Sirenia Capital Management LP and Alex Silverstein lists shared voting and dispositive power over 3,339,767 Common Shares, reported as 9.9% of the class. The amount includes 2,038,636 shares issuable upon full exercise of warrants held by Sirenia-managed funds. The 9.99% blocker is reflected in the reported percentage and currently prevents the reporting persons from exercising all the warrants; their actual beneficial ownership after the blocker is less than the reported share count.
Key Figures
Reported beneficial ownership:3,339,767 Common SharesOwnership percentage:9.9%Shares issuable upon warrant exercise:2,038,636 Common Shares+4 more
7 metrics
Reported beneficial ownership3,339,767 Common SharesEach reporting person reports the same shared position; includes shares issuable upon warrant exercise.
Ownership percentage9.9%Reported percentage gives effect to the 9.99% blocker.
Shares issuable upon warrant exercise2,038,636 Common SharesIncluded in the reported beneficial ownership amount; warrants are subject to the 9.99% blocker.
Warrant exercise blocker9.99%Limits exercise when it would cause the reporting persons to exceed this beneficial ownership level.
Share count used in ownership-percentage calculation13,511,531 Common SharesCalculation described as including 9,641,031 shares outstanding as of August 13, 2026 and 3,870,500 shares offered pursuant to the issuer's prospectus.
Shares outstanding9,641,031 Common SharesAs of August 13, 2026, as reported in the issuer's quarterly report.
Shares offered pursuant to prospectus3,870,500 Common SharesIncluded in the described share count used for the ownership-percentage calculation.
Key Terms
9.99% Blocker, Reported Warrants, beneficial ownership, shared voting power
4 terms
9.99% Blockerfinancial
"the Reported Warrants are subject to the 9.99% Blocker"
Reported Warrantsfinancial
"Common Shares issuable upon exercise of the Reported Warrants"
beneficial ownershipfinancial
"the actual number of Common Shares beneficially owned"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting powerfinancial
"Shared Voting Power 3,339,767.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many EDSA shares do Sirenia Capital Management and Alex Silverstein report?
They each report shared voting and dispositive power over 3,339,767 Common Shares, representing 9.9% of the class. The reported amount includes 2,038,636 shares issuable upon full exercise of warrants; actual beneficial ownership after the blocker is lower than the reported amount.
Can all the warrants held by Sirenia-managed funds be exercised now?
No. The warrants are subject to a 9.99% blocker, which prevents exercise to the extent it would cause the reporting persons to beneficially own more than 9.99% of Edesa's outstanding Common Shares. The reporting persons state they cannot currently exercise all of the warrants.
Who has rights to dividends or sale proceeds from more than 5% of EDSA shares?
SILV Fund, Ltd. has the right to receive or direct the receipt of dividends, or proceeds from sales, from more than 5% of Edesa's outstanding Common Shares.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Edesa Biotech, Inc.
(Name of Issuer)
Common Shares, without par value
(Title of Class of Securities)
27966L306
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
27966L306
1
Names of Reporting Persons
Sirenia Capital Management LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,339,767.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,339,767.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,339,767.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
IA, PN
Comment for Type of Reporting Person: Includes 2,038,636 Common Shares (as defined in Item 2(a)) issuable upon exercise of the Reported Warrants (as defined in Item 4(a)). As more fully described in Item 4, the Reported Warrants are subject to the 9.99% Blocker (as defined in Item 4(a)) and the percentage set forth on row (11) gives effect to the 9.99% Blocker. However, rows (6), (8) and (9) show the number of Common Shares that would be issuable upon the full exercise of the Reported Warrants and does not give effect to the 9.99% Blocker. Therefore, the actual number of Common Shares beneficially owned by such Reporting Person, after giving effect to the 9.99% Blocker, is less than the number of securities reported on rows (6), (8) and (9).
SCHEDULE 13G
CUSIP Number(s):
27966L306
1
Names of Reporting Persons
Alex Silverstein
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,339,767.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,339,767.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,339,767.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
HC, IN
Comment for Type of Reporting Person: Includes 2,038,636 Common Shares issuable upon exercise of the Reported Warrants. As more fully described in Item 4, the Reported Warrants are subject to the 9.99% Blocker and the percentage set forth on row (11) gives effect to the 9.99% Blocker. However, rows (6), (8) and (9) show the number of Common Shares that would be issuable upon the full exercise of the Reported Warrants and does not give effect to the 9.99% Blocker. Therefore, the actual number of Common Shares beneficially owned by such Reporting Person, after giving effect to the 9.99% Blocker, is less than the number of securities reported on rows (6), (8) and (9).
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Edesa Biotech, Inc.
(b)
Address of issuer's principal executive offices:
100 Spy Court, Markham, ON, Canada L3R 5H6
Item 2.
(a)
Name of person filing:
This statement is filed by:
(i) Sirenia Capital Management LP ("Sirenia") with respect to the common shares, without par value ("Common Shares"), of Edesa Biotech, Inc. (the "Issuer") held by, and issuable upon exercise of the Reported Warrants held by, investment funds it manages (collectively, the "Sirenia Funds"); and
(ii) Alex Silverstein ("Mr. Silverstein"), the managing member of Sirenia Capital Management GP LLC, the general partner of Sirenia, with respect to the Common Shares held by, and issuable upon exercise of the Reported Warrants held by, the Sirenia Funds.
The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of Sirenia and Mr. Silverstein is 1674 Meridian Avenue, Suite 320, Miami Beach, FL 33139.
(c)
Citizenship:
Sirenia is a Delaware limited partnership. Mr. Silverstein is a United States citizen.
(d)
Title of class of securities:
Common Shares, without par value
(e)
CUSIP No.:
27966L306
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 13,511,531 Common Shares outstanding, which is the sum of (i) the 3,870,500 Common Shares offered pursuant to the Issuer's Prospectus filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission (the "SEC") on August 20, 2026 and (ii) the 9,641,031 shares of Common Stock outstanding as of August 13, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 13, 2026, and assumes the exercise of the warrants (the "Reported Warrants") held by the Sirenia Funds.
Pursuant to the terms of the Reported Warrants, the Reporting Persons cannot exercise any of the Reported Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 9.99% of the outstanding Common Shares (the "9.99% Blocker") and the percentage set forth in Row (11) of the cover page for each of the Reporting Persons gives effect to the 9.99% Blocker. Consequently, at this time, the Reporting Persons are not able to exercise all of such Reported Warrants due to the 9.99% Blocker.
(b)
Percent of class:
9.9%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a). SILV Fund, Ltd. has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Common Shares.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See Item 2(a) and Item 3.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Sirenia Capital Management LP
Signature:
/s/ Kolby Loft
Name/Title:
Kolby Loft, General Counsel & Chief Compliance Officer